Why Sickle Cell Disease Is a Workplace Issue, Not Just a Health One.
Every September, Sickle Cell Awareness Month asks the public to understand a condition that has been part of Black communities for generations but has only recently started getting the attention, funding and workplace consideration it deserves.
For Black women in particular, who are disproportionately likely to be both patients and primary caregivers, sickle cell disease (SCD) sits at an exhausting intersection. An invisible illness, layered onto a healthcare system that too often does not believe their pain, layered onto workplaces that were not built with fluctuating, unpredictable conditions in mind.
Invisible Illness Meets Invisible Bias
SCD is the UK's most common and fastest-growing genetic blood disorder, affecting an estimated 15,000–17,500 people, with around 250 new cases diagnosed each year. It predominantly affects people of Black African and Caribbean heritage. The disease itself is punishing. Rigid, sickle-shaped red blood cells block blood vessels, triggering severe pain crises, chronic anaemia organ damage and a life expectancy that remains significantly shorter than the general population's.
But the clinical picture only tells half the story. The 2021 "No One's Listening" inquiry and the 2025 NHS Race and Health Observatory review, comparing SCD care to cystic fibrosis and haemophilia, found a pattern that many patients have described for years. SCD is treated as a lower priority.
There are roughly 0.5 specialist nurses per 100 SCD patients, compared with around 2 per 100 for cystic fibrosis patients. Research funding into SCD lags cystic fibrosis by a factor of roughly 2.5, despite SCD affecting more people in the UK. Hospital admissions for sickle cell rose 42% between 2013 and 2022, yet the services meant to absorb that need haven't scaled with it.
The human cost of that gap shows up in emergency departments, where patients in crisis describe being labelled "drug-seekers" having their pain dismissed and waiting far longer than NICE guidelines recommend for pain relief. This is not incidental. Reports link it directly to racial bias, including persistent and false myths about Black patients having a higher pain tolerance. For a condition that is, by definition, invisible from the outside, that bias becomes the difference between fast, adequate treatment and a dangerous delay.
This Lands Hardest For Black Women Professionals
For Black women, SCD rarely arrives as a standalone issue. Women are more likely to be the ones managing a partner's, child's or parent's crises alongside their own careers or living with the condition themselves while also carrying unpaid caregiving responsibilities.
That caregiving burden is compounded by workplace cultures that do not recognise fluctuating, unpredictable conditions as legitimate disabilities requiring flexibility.
UK research on Black and minority ethnic workers with SCD describes a specific, compounding set of barriers. Managers who do not understand the condition, difficulty getting reasonable adjustments even where equality law technically supports them, "hyper-ableist" workplace cultures that quietly punish rest or flexibility, stalled career progression and a real fear that disclosing the illness will be read as unreliability rather than a medical reality.
Layered onto the general experience of being a Black woman in many UK workplaces, where racial and gender bias already shape how competence and reliability are judged, SCD becomes something many people choose to hide rather than disclose. That silence has a cost. Missed accommodations, unmanaged fatigue and crises that could have been prevented with earlier support.
The indirect economic toll of all this is substantial. Studies estimate the combined cost of absenteeism, "presenteeism" (working through impairment), lost employment and early retirement linked to SCD runs into the hundreds of millions of dollars annually in extrapolated US figures alone and the caregiving burden behind those numbers disproportionately falls on women.
What Has Changed?
It would be inaccurate to say nothing has moved. Awareness campaigns, dating back informally to 1975 and gaining official recognition in the US in 1983, have shifted public understanding meaningfully.
Newborn screening is now standard across the US and UK, catching the condition early enough for penicillin prophylaxis, vaccination and hydroxyurea to change outcomes from childhood. Specialist NHS haemoglobinopathy services, Acute Sickle Cell Units in high-prevalence areas and staff e-learning modules exist because advocates pushed for them. Gene therapies like Casgevy now offer a genuine curative option for some patients, even if access remains narrow, current estimates suggest only around 50 patients a year can access it in some contexts.
High-profile patrons such as Professor Dame Elizabeth Anionwu, Baroness Floella Benjamin and public figures like supermodel Jourdan Dunn and actress Victoria Ekanoye have used their platforms to push trait awareness, blood donation and destigmatisation into mainstream visibility in a way that wouldn't have existed a generation ago.
What has not caught up is structural. Funding parity, workforce ratios, unbiased pain protocols and workplace policy. The 2025 NHS RHO review's recommendations, better data on SCD outcomes, dedicated research funding calls, expanded specialist workforce education, guaranteed access to curative therapies and bias-conscious clinical guidelines, are essentially a roadmap for closing that gap.
None of this requires new science. It requires the same seriousness of investment and belief that other genetic conditions already receive.
Workplace Parity
For Black women navigating SCD, whether as patients, mothers or caregivers, the ask is not sympathy, it is structural change. Employers who treat flexible hours and rest as reasonable adjustments rather than favours, colleagues who do not require visible proof of illness to believe it is real and healthcare providers who take reported pain at face value the first time, not the fifth.
Awareness months matter most when they translate into something concrete.
Donating blood (Black donors currently make up only around 2% of UK donors, despite being critical for matched transfusions), pushing employers toward genuine accommodation policies and supporting the funding and policy asks, from NICE guideline reform to specialist nurse ratios, that turn a month of recognition into a year-round system that actually listens.
If you are a Black woman navigating sickle cell disease in your own life, your family or your workplace, your story is part of what changes this. Comment below sharing what you wish colleagues, managers or the NHS understood.
Whether you are living with SCD, caring for someone who is or simply learning about it for the first time, if this piece gave you language for something you have struggled to explain at work, share it with a colleague, a manager or another woman in your network who needs to see it.
Awareness only becomes accountability when enough of us are willing to speak up, so let us keep this conversation and the pressure for real change going together.
